IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.314
EU - Europa 2.124
AS - Asia 2.010
SA - Sud America 478
AF - Africa 353
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.283
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.176
SG - Singapore 1.063
IT - Italia 839
CN - Cina 515
BR - Brasile 425
IE - Irlanda 334
CI - Costa d'Avorio 229
UA - Ucraina 219
RU - Federazione Russa 149
IN - India 139
DE - Germania 136
VN - Vietnam 114
CA - Canada 113
BE - Belgio 97
NL - Olanda 87
SN - Senegal 75
GB - Regno Unito 65
FI - Finlandia 44
KR - Corea 36
SE - Svezia 31
BD - Bangladesh 26
PL - Polonia 26
AR - Argentina 23
MX - Messico 19
FR - Francia 18
JP - Giappone 17
UZ - Uzbekistan 17
ES - Italia 16
TR - Turchia 14
ZA - Sudafrica 14
CZ - Repubblica Ceca 13
CH - Svizzera 12
HK - Hong Kong 12
NG - Nigeria 12
GR - Grecia 11
EC - Ecuador 10
IQ - Iraq 10
IR - Iran 9
ID - Indonesia 7
MA - Marocco 7
CO - Colombia 6
IL - Israele 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AT - Austria 5
BG - Bulgaria 5
LB - Libano 4
NO - Norvegia 4
PY - Paraguay 4
VE - Venezuela 4
AZ - Azerbaigian 3
BJ - Benin 3
DO - Repubblica Dominicana 3
KE - Kenya 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
AU - Australia 2
EG - Egitto 2
HU - Ungheria 2
KZ - Kazakistan 2
MY - Malesia 2
PK - Pakistan 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
GD - Grenada 1
IS - Islanda 1
JO - Giordania 1
LT - Lituania 1
NA - Namibia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
RO - Romania 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 9.283
Salva come PNG Salva come JPEG
Città #
Santa Clara 732
Dallas 703
Singapore 608
Chandler 443
Dublin 334
Chicago 284
Catania 232
Abidjan 229
Jacksonville 219
Ashburn 193
Boardman 125
Beijing 108
Kochi 104
Los Angeles 95
Cambridge 93
Lawrence 91
Andover 87
Nanjing 82
Dakar 74
Hefei 69
Grafing 64
Toronto 64
Civitanova Marche 59
New York 59
Rotterdam 55
Wingene 50
Des Moines 48
Wilmington 44
San Mateo 43
Moscow 40
Palermo 39
São Paulo 39
Seoul 35
Milan 34
Buffalo 32
Munich 30
Dong Ket 27
Hanoi 25
Brussels 24
Ho Chi Minh City 24
The Dalles 23
Montreal 22
Turku 22
Columbus 21
Ottawa 19
Rome 19
Seattle 19
Warsaw 19
Bari 18
Council Bluffs 17
Hebei 17
Nanchang 17
Shenyang 17
Tokyo 17
Jiaxing 16
Falls Church 15
Messina 15
Rio de Janeiro 15
Saint Petersburg 15
Belo Horizonte 14
Aci Catena 13
Changsha 13
Lappeenranta 13
Abuja 12
Bremen 12
Johannesburg 12
Santa Venerina 12
Brasília 11
Brno 11
Nijmegen 11
Phoenix 11
Boston 10
Orem 10
Poplar 10
Brooklyn 9
Helsinki 9
Hong Kong 9
Houston 9
Izegem 9
Pune 9
Tianjin 9
Chennai 8
Curitiba 8
Dhaka 8
London 8
Redmond 8
Redondo Beach 8
Reggio Emilia 8
San Francisco 8
San Giovanni la Punta 8
Tashkent 8
Denver 7
Mascalucia 7
Stockholm 7
Washington 7
Acireale 6
Amsterdam 6
Atlanta 6
Bernareggio 6
Leawood 6
Totale 6.459
Salva come PNG Salva come JPEG
Nome #
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 216
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 190
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 184
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 143
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 141
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 138
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 137
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 134
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 133
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 133
Comparative proteomic analysis of insulin receptor isoform A and B signaling 131
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 129
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 126
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 125
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 125
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 124
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 122
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 121
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 121
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 118
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 118
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 116
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 113
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 112
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 111
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 111
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 110
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 110
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 110
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 110
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 108
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 107
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 106
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 104
New insights in thyroid cancer and p53 family proteins 103
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 103
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 103
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 101
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 100
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 98
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 95
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 95
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 95
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 94
Opportunities and challenges of liquid biopsy in thyroid cancer 93
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 93
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 92
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 92
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 92
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 91
Uncommon long-term survival in a patient with chronic myeloid leukemia 90
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 90
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 89
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 85
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 84
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 83
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 82
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 81
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 81
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 81
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 80
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 80
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 79
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 78
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 77
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 77
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 77
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 76
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 76
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 75
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 74
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 71
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 71
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 69
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 65
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 65
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 65
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 64
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer 63
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 63
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 63
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 63
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 63
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 63
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 63
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 61
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 61
REThinking the role of the RET oncogene in breast cancer 60
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 60
Computational and biological characterization of nuclear import/export signals of the human BCR protein 60
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 60
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 59
IRF5 promotes the proliferation of human thyroid cancer cells. 59
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 59
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 57
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 55
No Benefit from Hydroxyurea Pre-Treatment in Frontline Chronic Myeloid Leukemia Therapy and Evidence of Quantitative Changes in the BCR::ABL1 Transcript Level 54
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 53
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 50
HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE? 47
Totale 9.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.787
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.787
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021424 0 0 0 0 128 16 51 3 106 4 68 48
2021/2022686 54 97 15 9 112 13 103 27 52 14 35 155
2022/20231.373 106 102 43 153 91 214 19 263 289 11 50 32
2023/2024766 57 107 30 36 32 184 11 44 7 35 133 90
2024/20252.956 111 445 116 175 585 394 191 80 187 203 315 154
2025/20262.549 300 272 790 377 810 0 0 0 0 0 0 0
Totale 9.478